Quick Answer
Inhibikase Therapeutics, Inc. reported Net Income Loss of -$48.26 million for the year ending 2025.
- Inhibikase Therapeutics, Inc. showed a decrease of -75.4% in Net Income Loss from 2024 to 2025.
- This data is from Inhibikase Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$547.4 thousand | Q2 2020: -$421.9 thousand | Q3 2020: -$670.6 thousand | Q1 2021: -$2.64 million | Q2 2021: -$2.64 million | Q3 2021: -$4.47 million | Q1 2022: -$4.64 million | Q2 2022: -$4.64 million | Q3 2022: -$4.49 million | Q1 2023: -$4.48 million | Q2 2023: -$5.78 million | Q3 2023: -$4.60 million | Q1 2024: -$4.65 million | Q2 2024: -$4.96 million | Q3 2024: -$5.78 million | Q1 2025: -$13.68 million | Q2 2025: -$9.92 million | Q3 2025: -$11.93 million.
- Over the full 6 years of available data (2020 to 2025), Inhibikase Therapeutics, Inc.'s Net Income Loss has declined by 1,594.6%.
- Historical annual values: Fiscal year 2025: -$48.26 million | Fiscal year 2024: -$27.52 million | Fiscal year 2023: -$19.03 million | Fiscal year 2022: -$18.05 million | Fiscal year 2021: -$14.79 million | Fiscal year 2020: -$2.85 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: